GlassScriptPhysician profile
Aruna Divakaran Poduval
NPI 1174773717
$2,846.43
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,723 · 2020: $81.68 · 2021: $42.00.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $2,300.00 | 2019 | |
| Abbvie INC. | $101.43 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $81.47 | 2019 | |
| Alexion Pharmaceuticals, INC. | $76.83 | 2019 | |
| Becton, Dickinson and Company | $51.83 | 2019 | |
| Insulet Corporation | $50.27 | 2019-2020 | |
| Lilly USA, LLC | $44.81 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $42.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $41.36 | 2019 | |
| Novo Nordisk INC | $38.14 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $18.29 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Poduval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.